Anand Patel, MD

Anand Patel, MD, is an assistant professor of medicine and medical director of Inpatient Leukemia Service at the University of Chicago Medicine.

Articles by Anand Patel, MD

Dr Patel on MRD Responses With Inotuzumab Ozogamicin Plus Dasatinib in Ph+ ALL

ByAnand Patel, MD

December 15th 2025

Anand Patel, MD, shares primary efficacy results from a phase 2 study evaluating a TKI plus inotuzumab ozogamicin–based therapy in newly diagnosed Ph-positive ALL.

Latest Updated Articles

Dr Patel on MRD Responses With Inotuzumab Ozogamicin Plus Dasatinib in Ph+ ALL
Published: December 15th 2025 | Updated:

Anand Patel, MD

Articles by Anand Patel, MD

Dr Patel on MRD Responses With Inotuzumab Ozogamicin Plus Dasatinib in Ph+ ALL

Latest Updated Articles

Trending on OncLive

FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression

FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma

Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD

Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer

Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma